GEMAROMAGem Aromatics Limited
Chemicals · Chemicals · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Gem Aromatics Limited manufactures and sells specialty ingredients in India, the United States, China, Brazil, Singapore, and internationally. The company offers mint and mint derivatives, such as peppermint, spearmint, and menthol; clove and clove derivatives, including clove oil, and eugenol and eugenol derivatives; phenol comprising anethole; and other ingredients, such as eucalyptus and eucalyptol, lemongrass, and other products for use in oral care, cosmetics, personal care, and other applications. The company was incorporated in 1997 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on GEMAROMA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 25/100)
- • Profit growth: -97.3% YoY
- • ROE: 0.3%
- • RSI: 38
- • MACD: bearish
Bull case
- • Debt/Equity: 0.34
- • Promoter holding: 75.8%
- • Golden cross setup: SMA50 above SMA200
- • Beta: 1.22
Bear case
- • Profit growth: -97.3% YoY
- • ROE: 0.3%
- • RSI: 38
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Profit growth: -97.3% YoY
- • ROE: 0.3%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹7.24). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.